Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.

J A Wagner1

  • 1Merck & Co Inc, Rahway, NJ 07065, USA. wagner@merck.com

Current Opinion in Molecular Therapeutics
|November 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbial detection in seroma fluid preceding the diagnosis of breast implant-associated anaplastic large cell lymphoma: a case report and review of the literature.

Case reports in plastic surgery & hand surgery·2020
Same author

Monetary reinforcement for self-monitoring of blood glucose among young people with type 1 diabetes: evaluating effects on psychosocial functioning.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same author

Advancing Clinical and Translational Science.

Clinical and translational science·2017
Same author

Transforming Translation: Impact of Clinical and Translational Science.

Clinical and translational science·2015
Same author

Perceptions about professionally and non-professionally trained hypoglycemia detection dogs.

Diabetes research and clinical practice·2015
Same author

Measuring Biomarker Progress.

Clinical pharmacology and therapeutics·2015
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Targeted Genetics is developing tgDCC-E1A, an E1A tumor suppressor gene therapy for solid tumors. Early trials show HER-2/neu downregulation and tumor response in breast and head/neck cancers.

Area of Science:

  • Oncology
  • Gene Therapy
  • Cancer Research

Background:

  • Targeted Genetics is developing tgDCC-E1A, a novel E1A tumor suppressor gene therapy.
  • This therapy utilizes a non-viral, lipid-based delivery system for solid tumors overexpressing the HER-2/neu oncogene.
  • Preclinical studies in mouse models demonstrated significant tumor reduction and increased survival rates.

Purpose of the Study:

  • To evaluate the safety and efficacy of tgDCC-E1A in patients with recurrent/refractory cancers.
  • To assess the gene therapy's ability to downregulate HER-2/neu expression and induce tumor response.
  • To determine optimal dosing and safety profiles for intratumoral liposomal-E1A gene therapy.

Main Methods:

  • Phase I dose-escalation studies involving patients with recurrent breast, ovarian, and head and neck cancers.

Related Experiment Videos

  • Intratumoral administration of liposomal-E1A gene therapy.
  • Phase II multicenter trial for recurrent head and neck squamous cell carcinoma.

    • Main Results:

    • Intratumoral E1A gene delivery resulted in HER-2/neu downregulation and tumor response.
    • In Phase I trials, nine out of 16 evaluable patients achieved stable disease, with two showing minor responses.
    • One patient showed no pathological evidence of tumor post-treatment, and four out of seven demonstrated HER-2/neu downregulation.

    Conclusions:

    • tgDCC-E1A demonstrates potential as a treatment for solid tumors, particularly those overexpressing HER-2/neu.
    • Intratumoral gene therapy with E1A can lead to HER-2/neu downregulation and clinical responses.
    • Ongoing Phase II trials aim to further establish the efficacy and safety of this gene therapy approach.